沙库巴曲缬沙坦钠对不同病程慢性心衰伴高血压患者及心室重构的影响研究

Abstract
Figure/Table
References
Related Citation (9)

Download: PDF (2054 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effects of sacubatrovalsartan sodium on chronic heart failure with hypertension and ventricular remodeling in patients with different courses of disease. Methods A total of 128 patients with chronic heart failure and hypertension admitted to our hospital from October 2021 to October 2022 were prospectively selected and divided into long course group and short course group according to the different course of disease, 64 cases each. The long-term group consists of patients with chronic heart failure and hypertension who have a disease course of more than 3 years; The short course group refers to patients with chronic heart failure and hypertension who have a course of 3 years or less. Both groups of patients were treated with Sacubatrovalsartan sodium. Compare the clinical outcomes, ventricular remodeling, and quality of life between the two groups of patients before and after treatment, as well as the event free survival status at a follow-up of 12 months. Results The total effective rate in the short course group (98.44%) and the long course group (78.12%) was significantly higher. After treatment, the level of left ventricular ejection fraction (LVEF) in the short course group was higher than that in the long course group, while the levels of interventricular septum thickness (IVS), left ventricular end systolic diameter (LVSD), left ventricular posterior wall thickness (LVPW) and left ventricular end diastolic diameter (LVEDD) were lower than those in the long course group. After treatment, the scores of physical, emotional and other fields and the Minnesota Heart Failure Quality of Life Scale (MLHFQ) in the short course group were lower than those in the long course group. The 12-month event-free survival rate in the short course group (98.44%) was higher than those in the long course group(89.06%). Conclusion Compared with patients with chronic heart failure and hypertension with a course of more than 3 years, Sakubactril valsartan sodium significantly improved the clinical outcome of patients with chronic heart failure and hypertension with a course of less than 3 years, and significantly improved ventricular remodeling, quality of life and event-free survival at 12 months follow-up.

Key words： sacubatro valsartan sodium chronic heart failure hypertension ventricular remodeling

Received: 16 November 2023

PACS:

R541

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Hongying
	YANG Jing
	YANG Bin
	KUANG Jingjie
	LONG Yan

Cite this article:

LI Hongying,YANG Jing,YANG Bin等. Study on the effect of Shakubaqu Valsartan sodium on chronic heart failure with hypertension and ventricular remodeling in patients with different courses of disease[J]. HuNan ShiFan DaXue XueBao(YiXueBan), 2024, 21(3): 78-81.

URL:

http://yxb.hunnu.edu.cn/EN/ OR http://yxb.hunnu.edu.cn/EN/Y2024/V21/I3/78

[1] 宋婷婷, 刘丽, 付志强, 等. H型高血压合并射血分数保留心衰患者血压昼夜节律与阵发性心房颤动的相关性[J]. 湖南师范大学学报: (医学版), 2021, 18(4): 4.
[2] EFREMOVA E V, SHUTOV A M, PETROVA E V .Personal Characteristics and Adaptation Mechanisms of Patients with Arterial Hypertension and Chronic Heart Failure[J]. The Russian Archives of Internal Medicine, 2021, 11(1): 34-42.
[3] 黄鑫涛, 白保强, 李之恒, 等. 不同剂量瑞舒伐他汀对老年高血压并射血分数保留型慢性心力衰竭患者心室重构的影响[J]. 重庆医科大学学报, 2022, 47(1): 66-73.
[4] 程德均, 王科程, 汤祥瑞. 通心络胶囊联合沙库巴曲缬沙坦对高血压合并慢性心力衰竭病人心功能及心室重构的影响[J]. 中西医结合心脑血管病杂志, 2023, 21(9): 1660-1663.
[5] 陈巧, 孙洁, 李竹青, 等. 沙库巴曲缬沙坦对心肌梗死后不同病程心力衰竭患者的疗效评价[J]. 天津医科大学学报, 2022, 28(3): 229-234.
[6] 中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789.
[7] 高血压联盟 (中国), 中国医疗保健国际交流促进会高血压分会, 中国高血压防治指南修订委员会, 等. 中国高血压防治指南 (2018年修订版)[J]. 中国心血管杂志, 2019, 24(1): 24-56.
[8] 张前, 范爱莉. 藏文版明尼苏达心力衰竭生活质量问卷 (MLHFQ) 在心力衰竭患者的应用[J]. 基础医学与临床, 2019, 39(11): 1612-1617.
[9] BARTNIK A, PEPKE-ZABA J, HOOLE S P, et al.Right ventricular-pulmonary artery coupling in chronic thromboembolic pulmonary hypertension[J]. Heart, 2023, 109(12): 898-904.
[10] MARRA A M, BENJAMIN N, CITTADINI A, et al.When Pulmonary Hypertension Complicates Heart Failure[J]. Cardiology clinics, 2022, 40(2): 191-198.
[11] 董旺黎, 雷杰喻, 师文涛. 不同剂量沙库巴曲缬沙坦治疗高血压合并慢性心力衰竭患者的临床疗效[J]. 医学临床研究, 2023, 40(7): 976-983.
[12] 李娜, 古丽孜热木·阿布都马那甫. 比较沙库巴曲缬沙坦和缬沙坦对高血压合并慢性心力衰竭患者血管内皮功能的影响[J]. 河北医学, 2021, 27(7): 1223-1227.
[13] 刘倩, 孟芳芳. 托拉塞米与呋塞米联合贝那普利治疗高血压合并慢性心力衰竭的疗效对比研究[J]. 山西医药杂志, 2022, 51(8): 902-904.
[14] 赵金艳, 崔少楠, 曹月娟. 沙库巴曲缬沙坦钠治疗老年高血压慢性心力衰竭的疗效观察[J]. 中华老年心脑血管病杂志, 2021, 23(12): 1268-1271.
[15] PASCUAL-FIGAL D, WACHTER R, SENNI M, et al.NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study[J]. JACC Heart Fail, 2020, 8(10): 822-833.
[16] 孙洁, 陈欣. 沙库巴曲缬沙坦对不同病程的慢性心力衰竭患者的疗效评价[J]. 临床心血管病杂志, 2021, 37(10): 942-946.
[17] MOON MG, HWANG IC, CHOI W, et al.Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction[J]. ESC Heart Fail, 2021, 8(3): 2058-2069.